This article has been updated to clarify the details of a study on confirmatory testing by Ambry Genetics.
NEW YORK (GenomeWeb) – Recognizing the growing popularity of direct-to-consumer (DTC) genetic testing services like 23andMe, clinical labs are being asked to verify results that indicate individuals have an increased risk for diseases like cancer, and some commercial insurers are even paying for this confirmatory testing.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.